165 related articles for article (PubMed ID: 29285035)
21. Biomarkers of everolimus efficacy in breast cancer therapy.
Voutsadakis IA
J Oncol Pharm Pract; 2022 Jun; 28(4):945-959. PubMed ID: 35018844
[TBL] [Abstract][Full Text] [Related]
22. Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an
Parachoniak CA; Rankin A; Gaffney B; Hartmaier R; Spritz D; Erlich RL; Miller VA; Morosini D; Stephens P; Ross JS; Keech J; Chmielecki J
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28550065
[TBL] [Abstract][Full Text] [Related]
23. Everolimus Reverses Palbociclib Resistance in ER+ Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway.
Chen L; Yang G; Dong H
Med Sci Monit; 2019 Jan; 25():77-86. PubMed ID: 30605443
[TBL] [Abstract][Full Text] [Related]
24. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
25. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
[TBL] [Abstract][Full Text] [Related]
26. Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer.
Okazaki M; Horimoto Y; Tanabe M; Ichikawa Y; Tokuda E; Arakawa A; Kobayashi T; Saito M
Med Oncol; 2018 Mar; 35(4):48. PubMed ID: 29520681
[TBL] [Abstract][Full Text] [Related]
27. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
28. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
29. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
30. Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
Mimoto R; Nihira NT; Hirooka S; Takeyama H; Yoshida K
Cancer Lett; 2017 Jan; 384():27-38. PubMed ID: 27746162
[TBL] [Abstract][Full Text] [Related]
31. [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
Gilabert M; Launay S; Gonçalves A
Bull Cancer; 2014 Mar; 101(3):325-33. PubMed ID: 24691195
[TBL] [Abstract][Full Text] [Related]
32. Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer.
Saksena R; Wong ST
Breast Cancer (Dove Med Press); 2013; 5():27-35. PubMed ID: 24648755
[TBL] [Abstract][Full Text] [Related]
33. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC
Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
[TBL] [Abstract][Full Text] [Related]
35. Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer.
Rugo HS
Clin Breast Cancer; 2016 Feb; 16(1):18-22. PubMed ID: 26507507
[TBL] [Abstract][Full Text] [Related]
36. New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer.
Vicier C; Dieci MV; Andre F
Curr Opin Oncol; 2013 Nov; 25(6):587-93. PubMed ID: 24097108
[TBL] [Abstract][Full Text] [Related]
37. Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.
Qiao L; Liang Y; Mira RR; Lu Y; Gu J; Zheng Q
Int J Clin Exp Med; 2014; 7(10):3333-43. PubMed ID: 25419366
[TBL] [Abstract][Full Text] [Related]
38. Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.
Ciruelos E; Cortes-Funes H; Ghanem I; Manso L; Arteaga C
Anticancer Drugs; 2013 Sep; 24(8):769-80. PubMed ID: 23838677
[TBL] [Abstract][Full Text] [Related]
39. Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway.
Shi Y; Zhang W; Ye Y; Cheng Y; Han L; Liu P; Zhao W; Tong Z; Yu J
Cancer Biol Med; 2018 Aug; 15(3):314-321. PubMed ID: 30197799
[TBL] [Abstract][Full Text] [Related]
40. Everolimus in the Treatment of Metastatic Breast Cancer.
Royce ME; Osman D
Breast Cancer (Auckl); 2015; 9():73-9. PubMed ID: 26417203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
